Literature DB >> 31301056

Evaluation of Safety and Efficacy of Growth Hormone Therapy by IGF-1 Z Score in Children with Short Stature.

Hui-Juan Liu1, Ling-Hong Wang2, Lu Chen2.   

Abstract

INTRODUCTION: This study aims to explore the safety and efficacy of growth hormone (GH) therapy by retrospectively analyzing the changes of insulin-like growth factor-1 (IGF-1) Z-scores in children with short stature after treatment with GH.
METHODS: The etiology of 104 children with short stature was classified according to the GH stimulation test and IGF-1 levels: (1) growth hormone deficiency (GHD); (2) mild growth hormone deficiency (M-GHD); (3) idiopathic short stature (ISS); (4) GH insensitivity syndrome (GHIS). In addition, all patients were treated with recombinant human growth hormone (rhGH) for 12 months, and the growth rate (Gv), height, body mass, bone age, height standard deviation scores (HtSDS), IGF-1 and adverse reactions were compared among these three groups before and after treatment.
RESULTS: The height, body mass, Gv and HtSDS were significantly higher in each group compared with those before treatment. Furthermore, the Z-score of IGF-1 significantly increased after 1 month of GH treatment and was positively correlated with the dosage of GH. Moreover, the difference in standard deviation score was significantly positively correlated with the increase in standard deviation score of IGF-1.
CONCLUSION: The detection of the GH-IGF-1 axis function can be carried out for the etiologic diagnosis of short stature. IGF-1 increased after rhGH treatment, and IGF-1 level was correlated to the time of therapy and dosage of GH. IGF-1-based GH dosing targeted to age- and gender-adjusted means may save medical costs and offer a more dose-sparing and potentially safer mode of therapy compared with traditional weight-based dosing.

Entities:  

Keywords:  Endocrinology; Growth hormone; Short status; Z-score of insulin-like growth factor-1

Mesh:

Substances:

Year:  2019        PMID: 31301056     DOI: 10.1007/s12325-019-01021-5

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  4 in total

1.  Effects of high-dose recombinant human growth hormone treatment on IGF-1 and IGFBP-3 levels in idiopathic dwarfism patients.

Authors:  Bin Wu; Honghua Lin; Jian Gao; Juan Sun; Meng Zhao
Journal:  Pak J Med Sci       Date:  2022 Mar-Apr       Impact factor: 2.340

2.  Short-term efficacy and safety of a lower dose of polyethylene glycol recombinant human growth hormone in children with growth hormone deficiency: A randomized, dose-comparison study.

Authors:  Zhouhong Jiang; Xuefeng Chen; Guanping Dong; Yin Lou; Jianping Zhang; Xinran Cheng; Jiayan Pan; Wei Liao; Jinzhun Wu; Xiaodong Huang; Xianjiang Jin; Deyun Liu; Ting Zeng; Shunye Zhu; Qin Dong; Xiaoming Luo; Dan Lan; Lizhi Cao; Xingxing Zhang; Jing Liu; Mingjuan Dai; Manyan Zhang; Li Liu; Junhua Dong; Dongmei Zhao; Shaoqing Ni; Junfen Fu
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

3.  Effect of growth hormone treatment on children with idiopathic short stature (ISS), idiopathic growth hormone deficiency (IGHD), small for gestational age (SGA) and Turner syndrome (TS) in a tertiary care center.

Authors:  Adnan Al Shaikh; Hadeer Daftardar; Abdul Aziz Alghamdi; Majd Jamjoom; Saniah Awidah; Mohamed E Ahmed; Ashraf T Soliman
Journal:  Acta Biomed       Date:  2020-03-19

4.  Association between Insulin-Like Growth Factor-1 and Relative Skeletal Maturation: A Retrospective Cohort Study of Short Children and Adolescents.

Authors:  Qianqian Zhao; Mei Zhang; Yuntian Chu; Baolan Ji; Hui Pan; Hailing Sun; Bo Ban
Journal:  Biomed Res Int       Date:  2020-08-13       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.